Drug intelligence / Profile preview

dexketoprofen + paracetamol

Development stage
Unknown
Lead developer
Berko İlaç
Modality
Small Molecules
Administration
Oral
01

Overview

Aseket is a fixed-dose combination of dexketoprofen (as dexketoprofen trometamol) and paracetamol (acetaminophen). Dexketoprofen is a non-steroidal anti-inflammatory drug (NSAID) that acts as a non-selective inhibitor of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), thereby reducing prostaglandin synthesis to alleviate pain and inflammation. Paracetamol is an analgesic and antipyretic agent that acts primarily on the central nervous system, potentially through the inhibition of cyclooxygenase activities in the brain and activation of descending serotonergic pathways. Developed by Berko İlaç, Aseket is approved in Turkey for the short-term symptomatic treatment of moderate to severe acute pain, including osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute gouty arthritis, acute musculoskeletal pain, postoperative pain, and dysmenorrhea.

Brand names
Aseket
Other names
dexketoprofen and paracetamoldexketoprofen trometamol + paracetamoldexketoprofen trometamol and paracetamoldexketoprofen/paracetamol
02

Targets

FAAHPGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)TRPV1 (Transient receptor potential cation channel subfamily V member 1)

Beyond the preview

Go deeper on dexketoprofen + paracetamol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on dexketoprofen + paracetamol.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call